It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Exosomes (small extracellular vesicles: EVs) have attracted increasing attention from basic scientists and clinicians since they play important roles in cell-to-cell communication in various biological processes. Various features of EVs have been elucidated regarding their contents, generation and secretion mechanisms, and functions in inflammation, regeneration, and cancers. These vesicles are reported to contain proteins, RNAs, microRNAs, DNAs, and lipids. Although the roles of individual components have been rigorously studied, the presence and roles of glycans in EVs have rarely been reported. In particular, glycosphingolipids in EVs have not been investigated to date. In this study, the expression and function of a representative cancer-associated ganglioside, GD2, in malignant melanomas was investigated. Generally, cancer-associated gangliosides have been shown to enhance malignant properties and signals in cancers. Notably, EVs derived from GD2-expressing melanomas enhanced the malignant phenotypes of GD2-negative melanomas, such as cell growth, invasion, and cell adhesion, in a dose-dependent manner. The EVs also induced increased phosphorylation of signaling molecules such as EGF receptor and focal adhesion kinase. These results suggest that EVs released from cancer-associated ganglioside-expressing cells exert many functions that have been reported as a function of these gangliosides and regulate microenvironments, including total aggravation of heterogeneous cancer tissues, leading to more malignant and advanced cancer types.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Chubu University College of Life and Health Sciences, Department of Biomedical Sciences, Kasugai, Japan (GRID:grid.254217.7) (ISNI:0000 0000 8868 2202)
2 Chubu University College of Life and Health Sciences, Department of Biomedical Sciences, Kasugai, Japan (GRID:grid.254217.7) (ISNI:0000 0000 8868 2202); Chubu University College of Life and Health Sciences, Department of Biomedical Sciences, Kasugai, Japan (GRID:grid.254217.7) (ISNI:0000 0000 8868 2202)
3 Chubu University College of Life and Health Sciences, Department of Clinical Engineering, Kasugai, Japan (GRID:grid.254217.7) (ISNI:0000 0000 8868 2202)
4 Chubu University College of Life and Health Sciences, Department of Biomedical Sciences, Kasugai, Japan (GRID:grid.254217.7) (ISNI:0000 0000 8868 2202); University of Chittagong, Department of Biochemistry and Molecular Biology, Chittagong, Bangladesh (GRID:grid.413089.7) (ISNI:0000 0000 9744 3393)
5 Tokushima University School of Dentistry, Department of Tissue Regeneration, Tokushima, Japan (GRID:grid.267335.6) (ISNI:0000 0001 1092 3579)
6 The Noguchi Institute, Laboratory of Glyco- Bioengineering, Itabashi, Japan (GRID:grid.472138.b) (ISNI:0000 0004 0617 4482)